Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen/CV Therapeutics CVT-124 target market will be diuretic-resistant hospitalized CHF patients.

Executive Summary

BIOGEN/CV THERAPEUTICS CVT-124 DEVELOPMENT WILL TARGET DIURETIC- RESISTANT hospitalized congestive heart failure patients, CV Therapeutics said in a recent public offering prospectus. The company estimates that one-quarter of the 875,000 patients hospitalized annually with a primary diagnosis of CHF exhibit resistance to diuretic treatments "due to excessive fluid reabsorption in the proximal tubule." CVT-124, the prospectus states, blocks "the adenosine A1 receptors in the proximal tubule that would ordinarily stimulate sodium reabsorption at that site."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel